Investors

  • 2021-09-14
    SUPPLEMENTAL AND CLARIFICATION ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION
  • 2021-09-13
    DISCLOSEABLE TRANSACTION (1) COVID-19 VACCINES LICENSE AGREEMENT; (2) COLLABORATION AND LICENSE AGREEMENT; AND (3) SHARE ISSUANCE AGREEMENT IN RESPECT OF THE MANUFACTURE, DEVELOPMENT AND COMMERCIALIZATION OF COVID-19 VACCINES AND CERTAIN LICENSED PRODUCTS
  • 2021-09-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED AUGUST 31, 2021
  • 2021-08-30
    VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
  • 2021-08-30
    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
  • 2021-08-26
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FIRST PERSON DOSED IN GLOBAL PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY IN CHINA FOR METASTATIC UROTHELIAL CANCER
  • 2021-08-16
    DATE OF BOARD MEETING
  • 2021-08-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED JULY 31, 2021
  • 2021-08-05
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NMPA FOR PHASE 3 TRIAL OF XERAVATM FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
  • 2021-07-29
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON TAIWAN FDA GRANTING PEDIATRIC AND RARE SEVERE DISEASE PRIORITY REVIEW DESIGNATION FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers